This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Zou Yang | |
|---|---|
| Name | Zou Yang |
| Birth date | c. 1970s |
| Birth place | Beijing |
| Fields | Virology, Immunology, Molecular biology |
| Institutions | Peking University, Tsinghua University, Chinese Academy of Sciences, Harvard University |
| Alma mater | Peking Union Medical College, University of Cambridge |
| Known for | Research on viral-host interactions; emerging infectious diseases |
Zou Yang is a Chinese virologist and molecular immunologist known for work on viral-host interactions, pathogenesis of emerging infectious diseases, and translational vaccine development. She has held positions at leading research institutions and contributed to international collaborations on influenza, coronaviruses, and antiviral therapeutics. Zou’s research spans basic molecular mechanisms to applied vaccine and antiviral strategies, informing public health responses and biomedical innovation.
Zou was born in Beijing and raised in a family with scientific and medical ties that included relatives affiliated with Peking Union Medical College and the Chinese Academy of Sciences. She completed undergraduate studies in biological sciences at Peking University and pursued doctoral training at the University of Cambridge, where she worked on virus-receptor interactions with mentors connected to Wellcome Trust-funded programs and collaborators from University of Oxford laboratories. Postdoctoral fellowships followed at Harvard University and in laboratories linked to Massachusetts Institute of Technology researchers, exposing her to cross-disciplinary teams funded by agencies such as the National Institutes of Health and the European Research Council.
Zou’s early faculty appointment was at Tsinghua University where she established a laboratory focused on RNA viruses and innate immunity, later transitioning to a senior research role at the Chinese Academy of Sciences. She has served as principal investigator on grants from the National Natural Science Foundation of China and participated in consortia with partners from Centers for Disease Control and Prevention (United States), World Health Organization, and the Bill & Melinda Gates Foundation. Zou has been an invited lecturer at Johns Hopkins University, Imperial College London, and Fudan University and has served on advisory boards for multinational pharmaceutical companies and public health institutions such as Pfizer, GlaxoSmithKline, and provincial health commissions.
Zou’s laboratory elucidated molecular determinants of viral entry, replication, and host restriction for influenza A viruses and betacoronaviruses, integrating techniques from cryo-electron microscopy collaborations with groups at Max Planck Institute and structural biology teams at Cold Spring Harbor Laboratory. Her team identified host factors that regulate interferon-stimulated responses, coordinating studies with investigators from National Institute of Allergy and Infectious Diseases and computational biologists at Stanford University for systems-level analyses. Work on viral evolution and zoonotic spillover drew on field studies with researchers at The Pirbright Institute and Wuhan Institute of Virology, informing risk assessments used by panels at the United Nations and advisory groups to the Chinese Center for Disease Control and Prevention.
Zou contributed to development of novel vaccine platforms, collaborating with groups at Moderna, academic teams at University of Oxford working on viral vectored vaccines, and industrial partners at Sinovac for antigen design and preclinical testing. Her publications include characterization of broad-spectrum antiviral candidates and monoclonal antibodies generated in partnership with biotech startups incubated by Tsinghua Holdings and translational units at Peking University Third Hospital.
Zou is author or co-author on articles published in leading journals such as Nature, Science, Cell, The Lancet, and Proceedings of the National Academy of Sciences. Key papers report structural analyses of viral glycoproteins in collaboration with teams from European Molecular Biology Laboratory and functional genomics studies with consortia associated with the Human Cell Atlas initiative. She has contributed chapters to edited volumes produced by Cold Spring Harbor Laboratory Press and served as guest editor for special issues in Nature Communications and PLoS Pathogens. Zou’s work has been cited by international reviews on influenza vaccinology and coronavirus countermeasures prepared for committees at the World Health Organization and the G20 health working groups.
Zou received the National Science Fund for Distinguished Young Scholars and was named to lists such as Nature’s 10-style recognitions in China for emerging scientific leaders. She has won institutional awards at Peking University and received prizes from professional societies including the International Society for Influenza and other Respiratory Virus Diseases and regional honors conferred by the Chinese Medical Association. Her advisory role on pandemic preparedness earned invitations to testify before panels convened by the National People’s Congress and to participate in expert workshops hosted by the World Health Organization and the Bill & Melinda Gates Foundation.
Zou maintains collaborative ties across academia, industry, and public health agencies, mentoring cohorts of scientists who have obtained positions at institutions such as Imperial College London, Johns Hopkins University, and the Chinese Academy of Sciences. Her legacy includes contributions to capacity-building initiatives for emerging infectious disease research in partnership with universities like Fudan University and public health training programs run with provincial CDCs and the World Health Organization. Colleagues note her role in fostering translational pipelines between basic research at Peking University and clinical development in biopharmaceutical firms, influencing responses to outbreaks and vaccine strategy discussions at international forums.
Category:Chinese virologists Category:20th-century births Category:21st-century scientists